To be eligible for treatment, the patient must either be refractory to standard active treatments and rescue therapies or have severe ITP and a high risk of bleeding that needs frequent course of rescue therapies.
The NICE recommendations are made on the proviso that the manufacturer provides eltrombopag with the discount agreed in the patient access scheme.